Moreover, using a siRNA screening approach, G9a was identified as a potential target in hematological malignancies such as acute lymphoblastic leukemia, acute myeloid leukemia (AML), lymphoma and MM cell lines. This evidence concerns the gene EHMT2 and acute myeloid leukemia.